

---

## P R E S S   R E L E A S E

---

### **Ypsomed and Terumo Corporation agree on collaboration**

**Burgdorf, October 3, 2014, 7 a.m. –Terumo Corporation, a Japanese global operating medical technology group, plans to supplement its range of products and services towards the pharmaceutical industry and integrate its prefillable polymer syringe PLAJEX™ into Ypsomed's autoinjector YpsoMate®. The first pharma customer has already placed an order for this new offering, with further customers expected.**

Japanese consumers and patients only accept flawless, top-quality products and packaging. That is why on the Japanese market, as opposed to elsewhere in the world, polymer-based prefilled syringes are well established as the preferred primary drug container for injectables. Such COP (Cyclic Olefin Polymer) PLAJEX™ syringes are manufactured by Terumo Corporation. Compared to prefilled syringes made of glass, PLAJEX™ is a silicone oil-free syringe system combined with Terumo's proprietary i-coating™ plunger stoppers, and has a higher level of break resistance. To supplement its own range of products, the multi-billion dollar group additionally plans to offer its customers the option of a compatible autoinjector into which the PLAJEX™ syringes are integrated. Having evaluated various suppliers and products the pharma customer of Terumo has selected Ypsomed's autoinjector. Quality and simplicity of use were the factors for the decision in favor of YpsoMate®.

The first Japanese pharmaceutical company now plans to place its drug product on the global market, packaged in the Terumo-Ypsomed injection system. For clinical trials Ypsomed will supply first YpsoMate® devices this year. Terumo and Ypsomed have presented the innovative combination of PLAJEX™ and YpsoMate® at international congresses in Basel, Düsseldorf and Tokyo. Due to the special features of the PLAJEX™ syringe with i-coating™ technology it is expected that they will continue to gain in importance in Japan and internationally.

For further information, please contact Benjamin Overney, Head of Investor & Public Relations at Ypsomed Holding AG, on telephone number +41 34 424 41 59 or by email ([benjamin.overney@ypsomed.com](mailto:benjamin.overney@ypsomed.com)).

### **About the Ypsomed Group**

The Ypsomed Group is the leading developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with almost 30 years of experience. Founded in 2003 from the well-known company Disetronic Medical Systems, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility, oncology and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetscare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading. Under the brand name mylife™ Diabetscare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements, and contract development and manufacturing, Ypsomed provides customer oriented product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf in Switzerland and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,000 employees.

### **About Terumo Corporation**

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with \$4.6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use and also supplies drug delivery/injection devices to pharmaceutical firms.

Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange.